Skip to main content
Top
Published in: Applied Health Economics and Health Policy 4/2015

01-08-2015 | Original Research Article

Productivity Losses Associated with Head and Neck Cancer Using the Human Capital and Friction Cost Approaches

Authors: Alison M. Pearce, Paul Hanly, Aileen Timmons, Paul M. Walsh, Ciaran O’Neill, Eleanor O’Sullivan, Rachael Gooberman-Hill, Audrey Alforque Thomas, Pamela Gallagher, Linda Sharp

Published in: Applied Health Economics and Health Policy | Issue 4/2015

Login to get access

Abstract

Objectives

Previous studies suggest that productivity losses associated with head and neck cancer (HNC) are higher than in other cancers. These studies have only assessed a single aspect of productivity loss, such as temporary absenteeism or premature mortality, and have only used the Human Capital Approach (HCA). The Friction Cost Approach (FCA) is increasingly recommended, although has not previously been used to assess lost production from HNC. The aim of this study was to estimate the lost productivity associated with HNC due to different types of absenteeism and premature mortality, using both the HCA and FCA.

Methods

Survey data on employment status were collected from 251 HNC survivors in Ireland and combined with population-level survival estimates and national wage data. The cost of temporary and permanent time off work, reduced working hours and premature mortality using both the HCA and FCA were calculated.

Results

Estimated total productivity losses per employed person of working age were EUR253,800 using HCA and EUR6800 using FCA. The main driver of HCA costs was premature mortality (38 % of total) while for FCA it was temporary time off (73 % of total).

Conclusions

The productivity losses associated with head and neck cancer are substantial, and return to work assistance could form an important part of rehabilitation. Use of both the HCA and FCA approaches allowed different drivers of productivity losses to be identified, due to the different assumptions of the two methods. For future estimates of productivity losses, the use of both approaches may be pragmatic.
Appendix
Available only for authorised users
Literature
1.
go back to reference National Cancer Registry Ireland. Cancers of the head and neck. Cancer trends No. 10. National Cancer Registry Ireland: Cork; 2011. National Cancer Registry Ireland. Cancers of the head and neck. Cancer trends No. 10. National Cancer Registry Ireland: Cork; 2011.
2.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.PubMedCrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.PubMedCrossRef
3.
go back to reference Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, Gravitt PE, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, DC. Head Neck. 2009;31(11):1393–422.PubMedCrossRef Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, Gravitt PE, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, DC. Head Neck. 2009;31(11):1393–422.PubMedCrossRef
4.
go back to reference Coughlan D, Frick KD. Economic impact of human papillomavirus-associated head and neck cancers in the United States. Otolaryngol Clin North Am. 2012;45:899–917.PubMedCrossRef Coughlan D, Frick KD. Economic impact of human papillomavirus-associated head and neck cancers in the United States. Otolaryngol Clin North Am. 2012;45:899–917.PubMedCrossRef
5.
go back to reference Buckwalter AE, Karnell LH, Smith RB, Christensen AJ, Funk GF. Patient-reported factors associated with discontinuing employment following head and neck cancer treatment. Arch Otolaryngol Head Neck Surg. 2007;133(May):464–70.PubMedCrossRef Buckwalter AE, Karnell LH, Smith RB, Christensen AJ, Funk GF. Patient-reported factors associated with discontinuing employment following head and neck cancer treatment. Arch Otolaryngol Head Neck Surg. 2007;133(May):464–70.PubMedCrossRef
6.
go back to reference Verdonck-de Leeuw IM, van Bleek WJ, Leemans CR, de Bree R. Employment and return to work in head and neck cancer survivors. Oral Oncology. 2010;46:56–60. Verdonck-de Leeuw IM, van Bleek WJ, Leemans CR, de Bree R. Employment and return to work in head and neck cancer survivors. Oral Oncology. 2010;46:56–60.
7.
go back to reference Chang KP, Lai CS, Hsieh TY, Wu YC, Chang CH. Two-year quality of life after free flap reconstruction in tumor-site discrepancy among Taiwanese with moderately advanced oral squamous cell carcinoma. World J Surg Oncol. 2012;10:145.PubMedCentralPubMedCrossRef Chang KP, Lai CS, Hsieh TY, Wu YC, Chang CH. Two-year quality of life after free flap reconstruction in tumor-site discrepancy among Taiwanese with moderately advanced oral squamous cell carcinoma. World J Surg Oncol. 2012;10:145.PubMedCentralPubMedCrossRef
8.
go back to reference Pearce AM, Timmons A, O’Sullivan E, Gallagher P, Gooberman-Hill R, Thomas AA, et al. Long-term workforce participation patterns following head and neck cancer. J Cancer Surviv. 2014 [Epub ahead of print]. Pearce AM, Timmons A, O’Sullivan E, Gallagher P, Gooberman-Hill R, Thomas AA, et al. Long-term workforce participation patterns following head and neck cancer. J Cancer Surviv. 2014 [Epub ahead of print].
9.
go back to reference Syse A, Tretli S, Kravdal O. Cancer’s impact on employment and earnings—a population-based study from Norway. J Cancer Surviv. 2008;2:149–58.PubMedCrossRef Syse A, Tretli S, Kravdal O. Cancer’s impact on employment and earnings—a population-based study from Norway. J Cancer Surviv. 2008;2:149–58.PubMedCrossRef
10.
go back to reference Ramirez MJF, Ferriol EE, Domenech FG, Llatas MC, Suarez-Varela MM, Martinez RL. Psychosocial adjustment in patients surgically treated for laryngeal cancer. Otolaryngol Head Neck Surg. 2003;129(1):92–7. Ramirez MJF, Ferriol EE, Domenech FG, Llatas MC, Suarez-Varela MM, Martinez RL. Psychosocial adjustment in patients surgically treated for laryngeal cancer. Otolaryngol Head Neck Surg. 2003;129(1):92–7.
11.
go back to reference Weisbrod B. Economics of public health. Philadelphia: University of Pannsylvania Press; 1961. Weisbrod B. Economics of public health. Philadelphia: University of Pannsylvania Press; 1961.
12.
go back to reference Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull. 1976;39:21–36.PubMed Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull. 1976;39:21–36.PubMed
13.
14.
go back to reference Koopmanschap MA, Rutten FF, Van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171–89.PubMedCrossRef Koopmanschap MA, Rutten FF, Van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171–89.PubMedCrossRef
15.
go back to reference Knies S, Severens JL, Ament AJHA, Evers SMAA. The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health. 2010;13(5):519–27.PubMedCrossRef Knies S, Severens JL, Ament AJHA, Evers SMAA. The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health. 2010;13(5):519–27.PubMedCrossRef
16.
go back to reference Ekwueme DU, Chesson HW, Zhang KB, Balamurugan A. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where Human Papillomavirus may be a risk factor for carcinogenesis—United States, 2003. Cancer. 2008;113(10 suppl):2936–45.PubMedCrossRef Ekwueme DU, Chesson HW, Zhang KB, Balamurugan A. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where Human Papillomavirus may be a risk factor for carcinogenesis—United States, 2003. Cancer. 2008;113(10 suppl):2936–45.PubMedCrossRef
17.
go back to reference Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst. 2008;100(24):1763–70.PubMedCentralPubMedCrossRef Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst. 2008;100(24):1763–70.PubMedCentralPubMedCrossRef
18.
go back to reference Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in France. Vaccine. 2011;29(32):5245–9. Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in France. Vaccine. 2011;29(32):5245–9.
23.
go back to reference Health Information and Quality Authority. Guidelines for the economic evaluation of health technologies in Ireland. In: Health Information and Quality Authority, editor. Health Information and Quality Authority; 2010. Health Information and Quality Authority. Guidelines for the economic evaluation of health technologies in Ireland. In: Health Information and Quality Authority, editor. Health Information and Quality Authority; 2010.
24.
go back to reference Hanly P, Koopmanschap MA, Sharp L. The friction cost approach in a changing macroeconomic environment: the case of colorectal cancer productivity costs. TBC. Draft. [under review]. Hanly P, Koopmanschap MA, Sharp L. The friction cost approach in a changing macroeconomic environment: the case of colorectal cancer productivity costs. TBC. Draft. [under review].
25.
go back to reference Hanly P, Timmons A, Walsh PM, Sharp L. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health. 2012;15(3):429–36.PubMedCrossRef Hanly P, Timmons A, Walsh PM, Sharp L. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health. 2012;15(3):429–36.PubMedCrossRef
26.
go back to reference Central Statistics Office. Irish life tables No. 15, 2005–2007. Dublin: Central Statistics Office; 2009. Central Statistics Office. Irish life tables No. 15, 2005–2007. Dublin: Central Statistics Office; 2009.
27.
go back to reference Hanly P, Walsh PM, Ó Céilleachair A, Skally M, Staines A, Kapur K, et al. Work-related productivity losses in an era of ageing populations: the case of colorectal cancer. J Occup Environ Med. 2013;55(2):128–34.PubMedCrossRef Hanly P, Walsh PM, Ó Céilleachair A, Skally M, Staines A, Kapur K, et al. Work-related productivity losses in an era of ageing populations: the case of colorectal cancer. J Occup Environ Med. 2013;55(2):128–34.PubMedCrossRef
28.
go back to reference Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ. 2005;6:30–313.CrossRef Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ. 2005;6:30–313.CrossRef
29.
go back to reference Penner JL. Psychosocial care of patients with head and neck cancer. Semin Oncol Nurs. 2009;25(3):231–41.PubMedCrossRef Penner JL. Psychosocial care of patients with head and neck cancer. Semin Oncol Nurs. 2009;25(3):231–41.PubMedCrossRef
30.
go back to reference Lensberg BR, Drummond MF, Danchenko N, Despiegel N, Francois C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res. 2013;5:565–73.PubMedCentralPubMedCrossRef Lensberg BR, Drummond MF, Danchenko N, Despiegel N, Francois C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res. 2013;5:565–73.PubMedCentralPubMedCrossRef
32.
go back to reference Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics. 2005;23(5):449–59.PubMedCrossRef Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics. 2005;23(5):449–59.PubMedCrossRef
33.
go back to reference Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13(1 (Part 1)):1–7. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13(1 (Part 1)):1–7.
Metadata
Title
Productivity Losses Associated with Head and Neck Cancer Using the Human Capital and Friction Cost Approaches
Authors
Alison M. Pearce
Paul Hanly
Aileen Timmons
Paul M. Walsh
Ciaran O’Neill
Eleanor O’Sullivan
Rachael Gooberman-Hill
Audrey Alforque Thomas
Pamela Gallagher
Linda Sharp
Publication date
01-08-2015
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 4/2015
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-015-0155-8

Other articles of this Issue 4/2015

Applied Health Economics and Health Policy 4/2015 Go to the issue